|Drug class||Vascular endothelial growth factor (VEGF) inhibitor|
|Main uses||Wet age-related macular degeneration (AMD)|
|Side effects||Blurry vision, cataracts, conjunctival bleeding, eye pain, increased intraocular pressure|
|Typical dose||0.3 mg|
|Elimination half-life||10 days|
|Chemical and physical data|
|Molar mass||~50 kg/mol|
Common side effects include blurry vision, cataracts, conjunctival bleeding, eye pain, and increased intraocular pressure. Other side effects may include anaphylaxis and endophthalmitis. It works by blocking vascular endothelial growth factor (VEGF).
Pegaptanib was approved for medical use in the United States in 2004. While it was approved in Europe in 2006, this approval was subsequently withdrawn. In the United States a vial of 0.3 mg costs about 780 USD. As of 2016 it is no longer available in the USA.
Pegaptanib is administered in a 0.3 mg dose once every six weeks by intravitreal injection. An intravitreal injection is one that is administered directly into the eye, more specifically, into the vitreous humour, or the jelly-like fluid within the eye. Pegaptanib has to be administered to the designated patient by an ophthalmologist in a sterile environment. Pegaptanib is marketed as a pre-filled syringe; however the syringe contains more than the recommended dose. Therefore, the eye care professionals must adjust the dose to the recommended amount before injections.
- Anterior chamber inflammation
- Raised intraocular pressure
- Punctate keratitis (small marks on the surface of the eye)
- Vitreous floaters (small particles or spots in the vision)
- Retinal damage (extremely adverse)
- Endophthalmitis (an infection inside the eye)
- Vitreous haemorrhage (bleeding inside of the eye)
Mechanism of action
Pegaptanib is a pegylated anti-vascular endothelial growth factor (VEGF) aptamer, a single strand of nucleic acid that binds with specificity to a particular target. Pegaptanib specifically binds to the 165 isoform of VEGF, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary pathological processes responsible for the vision loss associated with neovascular AMD.
Pegaptanib works as an antagonist to VEGF, which when injected into the eye blocks the actions of VEGF. This then reduces the growth of the blood vessels located within the eye and works to control the leakage and swelling.
Society and culture
It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing.  Outside the US pegaptanib is marketed by Pfizer.
The average cost of pegaptanib was approximately $5,300 per 5 syringes in the US. In 2004, when pegaptanib was approved it was a novel drug in its target and treatment for the treatment of AMD. However, the last large market sales occurred in 2010. Shortly after in 2011, sales began to decline due to the development of a more effective treatment, ranibizumab (a monoclonal antibody), and the cheaper bevacizumab.
Pegaptanib underwent several preclinical studies in order to determine its safety and efficacy before moving into clinical trials.
Toxicology studies were conducted in rhesus monkeys, guinea pigs, rats, mice, and rabbits. After the administration of the aptamer into rhesus monkeys, no toxic effects where exhibited. It was also noted that there was no change in intraocular pressure and no immune response was taken against the API[clarification needed]. Aside from the intravitreal administration of the pegaptanib, it was also found that subcutaneous and intravenous routes of administration were also effective at maintaining the desired blood plasma concentration. In rats, pegaptanib was successful at blocking VEGF-mediated vascular leakage almost entirely. The sustained release of the drug was tested in rabbits. It was found that using poly(lactic-co-glycolic) acid (PLGA) microspheres, which encapsulated the drug, the minimum dosing frequency was 6 weeks to maintain the desired pharmacological effect. This dosing interval is what carried over into the clinical trials and is still maintained today.
Phase I studies began in 1998 under Eyetech Pharmaceuticals. This study was conducted in 15 patients with wet AMD. Doses ranging from 0.25 to 30 mg per eye were injected into the eye, and patients were monitored for a period of three months. The results showed that 80% of the patients had stabilization or improvement, and 26.7% were showing improvement with no signs of toxicity.
After the success of the Phase I study, Eyetech completed a Phase II study focusing on multiple injections. In this study, 21 patients with subfoveal choroidal neovascularization (CNV) secondary to AMD were given multiple intravitreal injections. Due to the presence of subfoveal CNV some patients were given a secondary treatment, photodynamic therapy (PDT) for this condition. Results showed that in 87.5% of patients who received only pegaptanib, vision stabilized or improved. In patients who received PDT alone only 50.5% saw a slight improvement. However, when the two therapies were administered together, the level of improvement reached 60% or better.
After the success of the Phase I and Phase II trials, the FDA granted fast track designation for the Phase III clinical trials. In these trials, pegaptanib was studied in two identical controlled, double-blind randomized clinical studies that lasted for approximately two years each. For this study approximately 1200 patients with neovascular ("wet") age-related macular degeneration were randomly put into groups to receive either a placebo treatment or the designated 0.3 mg, 1 mg, or 3 mg of pegaptanib administered intravitreal injections every 6 weeks. Of the 1200 patients enrolled in the study approximately 892 received the varying doses of pegaptanib and approximately 298 received the placebo injection. At the end of the first year, patients continuing the study were re-randomized for the second year.
The primary efficacy endpoint for the study was denoted by the proportion of the patients who lost less than 15 letters of visual acuity from their assessed baseline over the 54-week assessment.
Results of the first year showcased promising results for pegaptanib. In groups treated with the 0.3 mg dose at the primary efficacy endpoint, experienced a statistically significant result.
- Study 1: 73% pegaptanib vs. 60% placebo
- Study 2: 67% pegaptanib vs. 53% placebo
Also, on average, pegaptanib 0.3 mg treated patients as well as the placebo patients continued to experience vision loss. However, the rate of vision decline was significantly lower than that of patients with the placebo treatment.
Moreover, it was also determined that the second year of treatment was less effective than the first year. Results of the primary efficacy endpoint are:
- Study 1: 57% pegaptanib vs. 56% placebo
- Study 2: 61% pegaptanib vs. 34% placebo
- Drug Information: Pegaptanib Sodium Injection Archived 2013-12-14 at the Wayback Machine
- "Pegaptanib Monograph for Professionals". Drugs.com. Archived from the original on 3 June 2021. Retrieved 26 October 2021.
- "Macugen (pegaptanib)" (PDF). European Medicines Agency: 1–3. 2010. Archived (PDF) from the original on 2013-12-13. Retrieved 2013-12-08.
- "MACUGEN- pegaptanib sodium injection, solution". dailymed.nlm.nih.gov. Archived from the original on 26 October 2021. Retrieved 26 October 2021.
- "Macugen". Archived from the original on 6 May 2021. Retrieved 26 October 2021.
- "Macugen Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 30 September 2020. Retrieved 26 October 2021.
- Wong, Randall (2016). "Ocular drug delivery systems" (PDF). Retina Today. Archived (PDF) from the original on 26 October 2021. Retrieved 26 October 2021.
- "Larry Gold and Craig Tuerk (NeXstar Pharmaceuticals, Boulder, USA)". European Patent Office. 2011-02-16. Archived from the original on 2013-12-14. Retrieved 2013-12-08.
- "Macugen product information". Evaluate. 2011. Archived from the original on 2021-10-20. Retrieved 2013-12-08.
- Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, et al. (2008). "Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up". Retina. 28 (10): 1387–94. doi:10.1097/IAE.0b013e3181884ff4. PMID 18827735. S2CID 8694305.
- "Eyetech Announces Approval of Macugen(R) in Brazil for the Treatment of Neovascular (Wet) Age-Related Macular Degeneration". Evaluate. 2005. Archived from the original on 2021-10-20. Retrieved 2013-12-08.
- Vinores SA (2006). "Pegaptanib in the treatment of wet, age-related macular degeneration". International Journal of Nanomedicine. 1 (3): 263–8. PMC 2426796. PMID 17717967.
- "Highlights of Prescribing Information (Macugen)". Food and Drug Administration: 3–12. July 2007.